Christopher Rovaldi Keros Therapeutics, Inc. (KROS) insider trading activity

KROS Quotes by TradingView

Christopher Rovaldi is Chief Operating Officer of Keros Therapeutics, Inc.. Currently has a direct ownership of 60,000 shares of KROS, which is worth approximately $901,800. The most recent transaction as insider was on Feb 18, 2025, when has been sold 60,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 60K
0% 3M change
Infinity% 12M change
Total Value Held $901,800

Christopher Rovaldi Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 18 2025
BUY
Grant, award, or other acquisition
-
60,000 Added 50.0%
60,000 Common Stock
Apr 06 2022
SELL
Open market or private sale
$112,320 $65.0 p/Share
1,728 Reduced 100.0%
0 Common Stock
Apr 06 2022
BUY
Exercise of conversion of derivative security
$27,648 $16.0 p/Share
1,728 Added 50.0%
1,728 Common Stock
Apr 01 2022
SELL
Open market or private sale
$49,118 $56.85 p/Share
864 Reduced 100.0%
0 Common Stock
Apr 01 2022
BUY
Exercise of conversion of derivative security
$13,824 $16.0 p/Share
864 Added 50.0%
864 Common Stock
CR

Christopher Rovaldi

Chief Operating Officer
Lexington, MA

Track Institutional and Insider Activities on KROS

Follow Keros Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KROS shares.

Notify only if

Insider Trading

Get notified when an Keros Therapeutics, Inc. insider buys or sells KROS shares.

Notify only if

News

Receive news related to Keros Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on KROS